Metabolites (May 2022)

Untargeted Metabolomics Identifies a Novel Panel of Markers for Autologous Blood Transfusion

  • Amna Al-Nesf,
  • Nada Mohamed-Ali,
  • Vanessa Acquaah,
  • Maneera Al-Jaber,
  • Maryam Al-Nesf,
  • Mohamed A. Yassin,
  • Nelson N Orie,
  • Sven Christian Voss,
  • Costas Georgakopoulos,
  • Rikesh Bhatt,
  • Alka Beotra,
  • Vidya Mohamed-Ali,
  • Mohammed Al-Maadheed

DOI
https://doi.org/10.3390/metabo12050425
Journal volume & issue
Vol. 12, no. 5
p. 425

Abstract

Read online

Untargeted metabolomics was used to analyze serum and urine samples for biomarkers of autologous blood transfusion (ABT). Red blood cell concentrates from donated blood were stored for 35–36 days prior to reinfusion into the donors. Participants were sampled at different time points post-donation and up to 7 days post-transfusion. Metabolomic profiling was performed using ACQUITY ultra performance liquid chromatography (UPLC), Q-Exactive high resolution/accurate mass spectrometer interfaced with a heated electrospray ionization (HESI-II) source and Orbitrap mass analyzer operated at 35,000 mass resolution. The markers of ABT were determined by principal component analysis and metabolites that had p 6H10O2 (2)* were downregulated. This is the first study to identify a panel of metabolites, from serum and urine, as markers of ABT. Once independently validated, it could be universally adopted to detect ABT.

Keywords